For the Inventor, By the Inventor

Enter assignee name

Brooklyn, NY, United States of America

Accutar Biotechnology Inc.

USPTO Granted Patents = 20

EPO Patents = 4

Trademarks = 2

Forward Citations = 28

Loading Chart...

Loading Chart...

11 inventors (with patents filed for the assignee):

Jie Fan (20 out of 23 patents)

Ke Liu (17 out of 22 patents)

Wei He (13 out of 16 patents)

4. Yimin Qian (10 out of 71 patents)

5. Hui Zhang (3 out of 3 patents)

6. Jie Su (2 out of 5 patents)

7. Ke Liu (2 out of 4 patents)

8. Xiangzhu Wang (1 out of 70 patents)

9. Xiangyan Sun (1 out of 1 patent)

10. Robert Zhiyong Luo (1 out of 15 patents)

11. Sun Xiangyan (1 out of 1 patent)

12. Robert Luo (3 patents)

20 patents: Sort by Forward Citations

1. 12338248 - Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors (2025-06-24),

2. 12331061 - Compounds having BET, estrogen receptor, and androgen receptor degradation activity and uses thereof (2025-06-17),

3. 11642342 - Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer (2023-05-09),

4. 11535606 - Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof (2022-12-27),

5. 11530222 - Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders (2022-12-20),

6. 11521712 - Computational method for classifying and predicting ligand docking conformations (2022-12-06),

7. 11420956 - Ureas having Androgen Receptor degradation activity and uses thereof (2022-08-23),

8. 11312702 - Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof (2022-04-26),

9. 11261178 - Chroman derivatives having estrogen receptor degradation activity and uses thereof (2022-03-01),

10. 11220490 - Ureas having androgen receptor degradation activity and uses thereof (2022-01-11),

11. 11117885 - Compounds having estrogen receptor alpha degradation activity and uses thereof (2021-09-14),

12. 10968212 - Compounds having estrogen receptor alpha degradation activity and uses thereof (2021-04-06),

13. 10923214 - Neural network for predicting drug property (2021-02-16),

14. 10836749 - Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof (2020-11-17),

15. 10800770 - Chroman derivatives having estrogen receptor degradation activity and uses thereof (2020-10-13),

Accutar Biotechnology Inc. is a leading biotechnology company dedicated to developing innovative therapies for various diseases. With a focus on precision medicine, we leverage cutting-edge technologies to discover and develop targeted solutions that improve patient outcomes. Our team of experts, including scientists, researchers, and clinicians, work collaboratively to advance our pipeline of therapeutic candidates. Through rigorous research and development, we aim to revolutionize healthcare and make a significant impact on patients' lives.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

20 Patents

#21 in Brooklyn, NY

#892 in New York

#15,890 in US

#30,364 in the World

Brooklyn, NY, United States of America

Accutar Biotechnology Inc.

Forward Citations = 28

11 inventors:

Jie Fan (20 out of 23 patents)

Ke Liu (17 out of 22 patents)

Wei He (13 out of 16 patents)

4. Yimin Qian (10 out of 71 patents)

5. Hui Zhang (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…